Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Explore BLENREP’s mechanism of action
BLENREP offers two different treatment combinations to meet your patients' needs: BVd and BPd2
BLENREP is indicated in adults for the treatment of multiple myeloma:
in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and
in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.2
Reach out to your local representative today to book a meeting and learn more about BLENREP
Prescribing information can be found here
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@gsk.com.
BLENREP is owned by or licensed to the GSK group of companies. ©2025 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.
References
- NICE. Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma www.nice.org.uk/guidance/gid-ta11203/documents .
- BLENREP. Summary of Product Characteristics. GlaxoSmithKline; 2025
June 2025 | PM-GB-BLM-WCNT-250001 (V2.0)
